MRKR · Marker Therapeutics, Inc.

Marker Therapeutics Inc Is A Clinical-Stage Immuno-Oncology Company Specializing In The Development And Commercialization Of Novel T Cell-Based Immunotherapies And Peptide-Based Vaccines For The Treatment Of Hematological Malignancies And Solid Tumor Indications. The Company Develops Product Candidates From Mar-T Cell Technology, Which Is Based On The Selective Expansion Of Non-Engineered, Tumor-Specific T Cells That Recognize Tumor-Associated Antigens, Or Taas, Which Are Tumor Targets, And Then Kill Tumor Cells. These T Cells Are Designed To Recognize Multiple Tumor Targets To Produce Broad Spectrum Anti-Tumor Activity. Its Pipeline Products Include: Autologous Mar-T Cell Product For The Treatment Of Lymphoma And Pancreatic Cancer (Mt-601), And Off-The-Shelf (Ots) Products (Mt-401-Ots).